Researchers tested psilocin, the active ingredient in magic mushrooms, and found it could reduce seizures in mice at low doses (3-5 mg/kg) without causing psychedelic effects. The anticonvulsant benefits were mediated through several brain pathways including serotonin, cannabinoid, opioid, and nitric oxide signaling systems. The effects persisted for at least 9 days after a single dose, suggesting psilocin may have potential as a new treatment for epilepsy, though human clinical trials are needed to confirm these findings.